Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Study of PRT-201 Administered After Arteriovenous Graft (AVG) Creation in Patients With Chronic Kidney Disease (PRT-201-102)

This study has been completed.
Information provided by (Responsible Party):
Proteon Therapeutics Identifier:
First received: October 22, 2009
Last updated: April 8, 2015
Last verified: April 2015
PRT-201 is a recombinant human type-I pancreatic elastase intended for local, long-lasting dilation of the AVG venous anastomosis and outflow vein. The goal of the treatment is to improve primary patency and long-term survival of AVGs and thereby provide patients with chronic kidney disease (CKD) a reliable and durable vascular access site for hemodialysis. Recent data indicate that up to three quarters of patients have loss of graft patency at one year, indicating a substantial need for new therapies. This clinical trial will explore the safety and dilatory effect of topically administered PRT-201 on the outflow vein of a newly placed upper extremity AVG.

Condition Intervention Phase
Chronic Kidney Disease
Drug: PRT-201
Drug: Placebo
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of a Single Dose of PRT-201 Administered Immediately After Arteriovenous Graft Creation in Patients With Chronic Kidney Disease

Resource links provided by NLM:

Further study details as provided by Proteon Therapeutics:

Primary Outcome Measures:
  • To assess the safety of a single topical dose of PRT-201. [ Time Frame: Day of AVG creation and 4 weeks After surgery. ]

Secondary Outcome Measures:
  • Primary graft patency [ Time Frame: 3, 6, 9 and 12 months after AVG creation. ]
  • Secondary graft patency. [ Time Frame: 3, 6, 9 and 12 months after AVG creation. ]

Enrollment: 89
Study Start Date: September 2009
Study Completion Date: November 2012
Primary Completion Date: November 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo Drug: Placebo
Applied topically during surgery
Experimental: PRT-201 Drug: PRT-201
Applied topically during surgery.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Age of at least 18 years.
  2. Chronic kidney disease with anticipated start of hemodialysis within 3 months or current hemodialysis dependence.
  3. Planned creation of a new upper extremity AVG or "jump" graft

Exclusion Criteria:

  1. Patients for whom this is the only potential site for an upper extremity vascular access.
  2. Creation of a new AVG or "jump" graft in an upper extremity previously treated with an investigational gene or cell based therapy, or locally with an investigational pharmacological agent.
  3. On physical examination or by other means, suspected proximal vein stenosis, occlusion, lack of continuity with the subclavian vein, central venous stenosis or central venous occlusion.
  4. History or presence of an arterial aneurysm.
  5. Previous treatment with PRT-201.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01001351

United States, California
Ladenheim Dialysis Access Center
Fresno, California, United States, 93710
California Institute of Renal Research
San Diego, California, United States, 92123
United States, District of Columbia
Washington Hospital/Medstar Research
Washington, District of Columbia, United States, 20010
United States, Indiana
Indiana/Ohio Heart
Fort Wayne, Indiana, United States, 46804
Indiana University/Purdue University
Indianapolis, Indiana, United States, 46202
United States, Kentucky
University of Louisville
Louisville, Kentucky, United States, 40202
United States, Louisiana
Vascular Specialty Center
Baton Rouge, Louisiana, United States, 70809
United States, Massachusetts
Brigham & Women's Hospital
Boston, Massachusetts, United States, 02115
University of Massachusetts
Worcester, Massachusetts, United States, 01655
United States, New York
Weill Cornell Medical College
New York, New York, United States, 10065
United States, North Carolina
Duke University Medical Center
Durham, North Carolina, United States, 27710
United States, Ohio
University of Cincinnati
Cincinnati, Ohio, United States, 45267
United States, South Carolina
Greenville Memorial Hospital
Greenville, South Carolina, United States, 29615
United States, Texas
The Methodist Hospital
Houston, Texas, United States, 77030
Peripheral Vascular Associates
San Antonio, Texas, United States, 78205
United States, Virginia
Sentara Vascular Specialists
Norfolk, Virginia, United States, 23507
Sponsors and Collaborators
Proteon Therapeutics
Study Director: Marco Wong, MD, PhD Proteon Therapeutics, Inc
  More Information

Responsible Party: Proteon Therapeutics Identifier: NCT01001351     History of Changes
Other Study ID Numbers: PRT-201-102
Study First Received: October 22, 2009
Last Updated: April 8, 2015

Keywords provided by Proteon Therapeutics:
Chronic Kidney Disease
Arteriovenous Grafts (AVG)
Vascular Access

Additional relevant MeSH terms:
Kidney Diseases
Renal Insufficiency, Chronic
Urologic Diseases
Renal Insufficiency processed this record on April 27, 2017